share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Jordt Raymond M

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Jordt Raymond M

Altimmune | 4:持股變動聲明-高管 Jordt Raymond M
美股SEC公告 ·  08/01 17:46

Moomoo AI 已提取核心訊息

Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 917 shares of common stock on July 31, 2024. The transaction was carried out directly with the shares valued at $5.41 each. Following this acquisition, Jordt's total direct holdings in the company increased to 14,660 shares. The transaction is part of a grant, award, or other acquisition, as per the transaction code description provided.
Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 917 shares of common stock on July 31, 2024. The transaction was carried out directly with the shares valued at $5.41 each. Following this acquisition, Jordt's total direct holdings in the company increased to 14,660 shares. The transaction is part of a grant, award, or other acquisition, as per the transaction code description provided.
Altimmune, Inc.的首席業務官Raymond M. Jordt於2024年7月31日完成了購買917股普通股的交易。該交易直接與股票價值爲每股5.41美元的股票進行。在此次收購之後,Jordt在公司的直接持股總數增加到14,660股。該交易屬於授予、獎勵或其他收購,根據交易代碼說明提供。
Altimmune, Inc.的首席業務官Raymond M. Jordt於2024年7月31日完成了購買917股普通股的交易。該交易直接與股票價值爲每股5.41美元的股票進行。在此次收購之後,Jordt在公司的直接持股總數增加到14,660股。該交易屬於授予、獎勵或其他收購,根據交易代碼說明提供。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息